Apotex seeks to raise C$1.2B in Toronto IPO, marking a major test for Canada’s public markets

Apotex Health Corp., one of Canada’s largest pharmaceutical companies, is preparing to go public on the Toronto Stock Exchange with an offering that could raise up to C$1.2 billion. The company filed a preliminary prospectus on May 28, 2026, under the ticker APTX.

What the offering looks like

The IPO is structured as a mix of newly issued treasury shares and secondary shares. The secondary component comes primarily from SK Capital Partners, the controlling shareholder looking to monetize part of its stake.

Estimates for the offering size range between C$750 million and C$1 billion, with a potential upper ceiling of C$1.2 billion depending on demand.

Apotex’s financials give the listing some serious backing. The company reported C$3.5 billion in revenue alongside C$374 million in earnings.

Apotex has built its business around the generics pharmaceutical market, operating across the Americas and India with a substantial workforce.

Strategic context and recent moves

In April 2026, the company struck a partnership with Cumberland Pharmaceuticals aimed at expanding its specialty drug portfolio in the US market.

SK Capital Partners, the private equity firm that controls Apotex, is using the IPO partly as a liquidity event. The inclusion of secondary shares in the offering means some of the proceeds go directly to existing shareholders rather than into company coffers.

What this means for investors

The valuation math starts with those C$3.5 billion in revenue and C$374 million in earnings. Comparable generics companies tend to trade at modest earnings multiples relative to the broader pharma sector.

The Cumberland Pharmaceuticals partnership adds a wrinkle worth monitoring. If Apotex can successfully build out its US specialty drug presence, that changes the growth narrative meaningfully, as specialty pharma commands higher margins and stickier revenue streams.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.